Skip to Main Content

Paper Details

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).
Nat Commun
42
2020
Author NameAffiliation
Michael F PressKeck School of Medicine, University of Southern California
Joan S BruggeHarvard Medical School
Christina CurtisStanford University School of Medicine
Christina CurtisStanford Cancer Institute, Stanford University School of Medicine
Christina CurtisStanford University School of Medicine
Dennis J SlamonDavid Geffen School of Medicine, University of California Los Angeles
  • 1 - 6

Datasets

Release 1.2